Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2400
+0.0100 (4.35%)
At close: Mar 26, 2026
Market Cap15.65M +313.2%
Revenue (ttm)n/a
Net Income-2.59M
EPS-0.00
Shares Out6.81B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,877,920
Average Volume30,185,707
Open0.2300
Previous Close0.2300
Day's Range0.2220 - 0.2500
52-Week Range0.1095 - 0.4000
Beta1.38
RSI46.90
Earnings DateApr 16, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer... [Read more]

Founded 2017
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements